Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Chronic myelogenous leukemia.

Michael E O'Dwyer¹

¹Department of Hematology, University College Hospital, Galway, Ireland. michael.odwyer@whb.ie

Current Opinion in Oncology

|December 20, 2002

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Targeting intrinsic apoptosis rewires human NK cell persistence: NOXA as a dominant survival switch.

Molecular therapy. Oncology·2026

Same author

Blood Cancer Network Ireland (BCNI) and National Cancer Registry Ireland (NCRI) collaboration: challenges and utility of an Enhanced Blood Cancer Outcomes Registry (EBCOR) pilot.

Irish journal of medical science·2024

Same author

Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.

Cell reports·2023

Same author

Concurrent transposon engineering and CRISPR/Cas9 genome editing of primary CLL-1 chimeric antigen receptor-natural killer cells.

Cytotherapy·2022

Same author

Targeting hypersialylation in multiple myeloma represents a novel approach to enhance NK cell-mediated tumor responses.

Blood advances·2022

Same author

Phase 2 studies of lenalidomide, subcutaneous bortezomib, and dexamethasone as induction therapy in patients with newly diagnosed multiple myeloma.

American journal of hematology·2022

Imatinib mesylate has transformed chronic myelogenous leukemia (CML) treatment. This review covers imatinib"s use in various CML phases, resistance, and stem cell transplantation strategies.

Area of Science:

Hematology
Oncology
Pharmacology

Background:

Chronic myelogenous leukemia (CML) management has been revolutionized by imatinib mesylate.
Understanding imatinib's role across CML phases is crucial.

Purpose of the Study:

To review recent advances in CML treatment, focusing on imatinib.
To discuss optimal therapy for newly diagnosed CML patients.
To explore imatinib resistance and stem cell transplantation in CML.

Main Methods:

Literature review of recent studies on imatinib in CML.
Analysis of clinical trial data and treatment guidelines.
Synthesis of information on CML management strategies.

Main Results:

Related Experiment Videos

Maturing data support imatinib use in various CML phases.
Strategies for overcoming imatinib resistance are emerging.
Stem cell transplantation remains relevant in specific CML treatment algorithms.

Conclusions:

Imatinib mesylate is a cornerstone therapy for chronic myelogenous leukemia.
Addressing imatinib resistance and refining treatment algorithms are key ongoing challenges.
Personalized treatment approaches are essential for optimal CML patient outcomes.